HPGC Renmintongtai Pharmaceutical Corporation (600829.SS)
- Previous Close
6.22 - Open
6.19 - Bid 6.28 x --
- Ask 6.29 x --
- Day's Range
6.19 - 6.39 - 52 Week Range
4.96 - 10.50 - Volume
5,371,578 - Avg. Volume
6,874,345 - Market Cap (intraday)
3.642B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
12.08 - EPS (TTM)
0.52 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 27, 2021
- 1y Target Est
--
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese medicines, Chinese herbal medicine, antibiotics, biological products, and biochemical drugs, as well as medical equipment and health products. It also provides logistics services, including warehousing and distribution; and hospital services comprising medical treatment, prevention, health care, rehabilitation, blood purification, and renal disease treatment. In addition, the company offers Chinese and Western medicines, Chinese herbal medicines, nourishing health care products, medical equipment, cosmetics, and daily necessities through an e-commerce platform. It operates chain stores in Heilongjiang Province. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.
www.hyrmtt.com.cn2,960
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 600829.SS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600829.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600829.SS
Valuation Measures
Market Cap
3.61B
Enterprise Value
3.71B
Trailing P/E
12.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
1.27
Enterprise Value/Revenue
0.36
Enterprise Value/EBITDA
8.75
Financial Highlights
Profitability and Income Statement
Profit Margin
2.89%
Return on Assets (ttm)
3.58%
Return on Equity (ttm)
11.13%
Revenue (ttm)
10.33B
Net Income Avi to Common (ttm)
298.71M
Diluted EPS (ttm)
0.52
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05B
Total Debt/Equity (mrq)
40.84%
Levered Free Cash Flow (ttm)
1.76M
Research Analysis: 600829.SS
Company Insights: 600829.SS
600829.SS does not have Company Insights